Fresenius SE & Co. (OTCMKTS:FSNUY) Sees Unusually-High Trading Volume - Here's What Happened

Key Points

• Unusually-high trading volume: About 109,135 shares traded mid-day (a 45% rise from 75,481), with the stock last at $13.24 (up from $12.96) and roughly +2.2% on the day.
• Analyst sentiment: Citigroup reissued a "Buy" and three analysts currently rate Fresenius with a consensus "Buy" recommendation.
• Recent results & valuation: Fresenius reported Q EPS of $0.28 on $6.94B revenue, has a P/E of 21.02 and market cap of about $29.8B, and analysts project roughly 0.79 EPS for the year.

Shares of Fresenius SE & Co. (OTCMKTS:FSNUY - Get Free Report) saw unusually-strong trading volume on Friday . Approximately 109,135 shares traded hands during mid-day trading, an increase of 45% from the previous session's volume of 75,481 shares.The stock last traded at $13.24 and had previously closed at $12.96.

Wall Street Analyst Weigh In

Separately, Citigroup reissued a "buy" rating on shares of Fresenius SE & Co. in a research report on Tuesday, February 3rd. Three investment analysts have rated the stock with a Buy rating, According to data from MarketBeat, Fresenius SE & Co. presently has a consensus rating of "Buy".

Fresenius SE & Co. Stock Up 2.2%

The firm's 50-day simple moving average is $13.82 and its 200 day simple moving average is $14.29. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.00 and a current ratio of 1.32. The stock has a market capitalization of $29.83 billion, a P/E ratio of 21.02 and a beta of 0.81.

Fresenius SE & Co. (OTCMKTS:FSNUY - Get Free Report) last issued its quarterly earnings results on Wednesday, February 25th. The company reported $0.28 EPS for the quarter. Fresenius SE & Co. had a net margin of 5.71% and a return on equity of 10.31%. The firm had revenue of $6.94 billion for the quarter. As a group, research analysts expect that Fresenius SE & Co. will post 0.79 EPS for the current year.

About Fresenius SE & Co.

Fresenius SE & Co KGaA is a global healthcare group headquartered in Bad Homburg vor der Höhe, Germany. Founded in 1912 by Eduard Fresenius, the company has grown into one of the world's leading providers of products and services for dialysis, hospitals and outpatient medical care. Trading on major European exchanges and available over the counter in the U.S. as FSNUY, Fresenius SE & Co brings together a portfolio of specialized healthcare businesses under one corporate umbrella.

The company operates through four main business segments.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.